transplantation. In conclusion, we report a simple and rapid protocol for in vitro differentiation of mouse iPSCs into AECs. Differentiated iPSCs show potential for regenerating three-dimensional alveolar lung structure and can be used to abrogate lung injury.
INTRODUCTION
In the advanced stage of acute and chronic lung diseases, such as acute lung injuries, idiopathic pulmonary fibrosis (IPF), and chronic obstructive lung disease (COPD), present medications can only stabilize the disease conditions or delay disease progression. Although lung transplantation is the only definitive option for these advanced-stage lung diseases, donor organ shortage is a major problem.
Tissue engineering regenerative medicine is a new multidisciplinary field for exchanging impaired cells or tissues with new functional cells or tissues. The first step in regenerative medicine for end-stage lung diseases is generation of alveolar epithelium containing two cell types: alveolar epithelial type I and type II cells (AEC I and II). AEC I cells are large, flattened cells comprising 95% of the alveolar lining area and are responsible for gas exchange, whereas AEC II cells are cuboidal cells, more abundant but smaller than AEC I cells, which comprise 5% of the alveolar lining area [1, 2] . AEC I cells are terminally differentiated, unable to replicate, and are susceptible to environmental toxicants and pathogens. In the event of lung damage, although AEC II cells have been shown to undergo proliferation and/or differentiation to AEC I cells to repair the damaged alveolar epithelium, this repair process often causes inappropriate reconstruction of lung structures [1, 3, 4] .
Embryonic stem cells (ESCs) are self-renewing pluripotent cells that can differentiate into alveolar epithelial cells in vitro [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . The problems of immune rejection and ethical issues restrict clinical application of ESCs. Induced pluripotent stem cells (iPSCs), which are derived from differentiated somatic cells by introduction of several defined transcription factors, display self-renewal properties and pluripotency similar to ESCs [17, 18] . Additionally, they have the potential to overcome the abovementioned limitations. Recently, several studies have reported in vitro differentiation to AEC II-like cells from iPSCs [19, 20] .
In the present study, we differentiated mouse iPSCs into AECs in vitro and investigated the regenerative and therapeutic potential of those differentiated iPSCs in mouse models.
We used a previously reported two-step protocol to differentiate iPSCs into AECs.
Although most ESC differentiation protocols have used the conventional embryoid body (EB) method [9] , we achieved iPSC differentiation using a dissociated low-density seeding method that is considered more rapid and effective [10] . We tested six medium combinations to identify the most efficient protocol and successfully differentiated mouse iPSCs into AEC-like cells. The regenerative potential was demonstrated through seeding of the differentiated iPSCs into decellularized mouse lung scaffolds. Their therapeutic potential was demonstrated in a bleomycin-induced mouse acute lung injury model.
MATERIALS AND METHODS

Cell Line and Cell Culture
A mouse iPS cell line (iPS-MEF-Ng-492B-4) obtained from the RIKEN Cell Bank (Tsukuba, Japan) was maintained on 1×10 4 cells/cm 2 mitomycin-C (Sigma-Aldrich, St
Louis, MO, USA)-inactivated mouse SNL76/7 cells (ECACC; #EC07032801) as a feeder layer on 0.1% gelatin-coated tissue culture dishes in iPS medium containing high-glucose Dulbecco's modified Eagle's medium (DMEM; Gibco, Carlsbad, CA, USA) supplemented with 15% ES cell fetal bovine serum (FBS; Gibco), 0.1 mM nonessential amino acids (Gibco), 0.1 mM 2-mercaptoethanol (Gibco), 1000 U/ml mLIF (Chemicon, Temecula, CA, USA), 50 U/mL penicillin, and 50 mg/mL streptomycin (Gibco).
The murine type II pneumocyte cell line MLE12 was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA; #CRL-2110) and was cultured in medium containing 50% DMEM (Gibco) and 50% Ham's F12 medium (Gibco)
supplemented with 10 nM hydrocortisone (Sigma-Aldrich), 10 nM -estradiol (Sigma-Aldrich), 10 nM HEPES (Sigma-Aldrich), 2 nM L-glutamine (Gibco), 1% ITS (Gibco), 2% FBS (Gibco), 50 U/mL penicillin, and 50 mg/mL streptomycin (Gibco).
Mouse iPSC Differentiation
Mouse iPSCs were induced to differentiate into AECII-like cells using the dissociated seeding method for murine ESCs described previously, with slight modifications [10] .
As shown in Figure 1A , at first, mouse iPSCs were trypsinized, centrifuged, resuspended in iPS medium, and plated at a lower density (1×10 3 cells/cm 2 ) on 0.1% gelatin-coated tissue culture dishes for 24 h. Next, the iPS medium was changed to basic differentiation medium (Basic DM) supplemented with 20 ng/ml Activin A (R&D Systems, Minneapolis, MN, USA) and 10 ng/ml Wnt3a (R&D Systems), and then incubated for 6 days (D1-D7). Basic DM contains 75% IMDM (Gibco) and 25% Ham's F12 medium (Gibco) supplemented with 0.5× of both N2 and B27 (without retinoic acid) supplements (Gibco), 50 U/ml penicillin, 50 mg/ml streptomycin, 2 mM glutamine (Gibco), 0.5 mM ascorbic acid (Sigma-Aldrich), 4.5×10 -4 M 1-thioglycerol (Sigma-Aldrich), and 0.05% bovine serum albumin (BSA; Sigma-Aldrich). Next, the differentiation medium was changed to fresh Basic DM or small-airway basal medium (SABM) (Lonza, Walkersville, MD, USA) supplemented with 50 ng/ml FGF2 (Sigma-Aldrich) and 50 µg/ml heparin sulfate salt (Sigma-Aldrich), followed by incubation for a further 5 days.
Immunofluorescence
Mouse lung tissues were frozen or fixed with 4% paraformaldehyde and embedded in paraffin. Paraffin-embedded sections were deparaffinized, and antigen retrieval was subsequently performed by autoclaving the tissue sections in antigen retrieval solution 
Transmission Electron Microscopy (TEM)
The murine type II pneumocyte cell line MLE12 and mouse iPSCs were washed with oxide/Epon at room temperature overnight. The following day, the samples were centrifuged for 3 min at 800 g, infiltrated at 1:4 propylene oxide/Epon at room temperature for 1 h, centrifuged for 3 min at 800 g again, exposed to 100% Epon for 1 h at room temperature, and finally incubated at 60°C for 48 h. Ultrathin sections (50 nm) were cut and collected on sheet mesh, stained with uranyl acetate and lead citrate.
The stained sections were examined and photographed in a JEM-1230 TEM (JEOL, Tokyo, Japan) at 80-kV voltage.
Lung Decellularization and Recellularization
Mouse lung decellularization and recellularization were performed according to methods reported recently [15, 21] . Briefly, harvested heart-lung blocs were decellularized by injection of 0.1% sodium dodecyl sulfate (Sigma-Aldrich) and 1%
Triton X-100 (Sigma-Aldrich) through both the right ventricle and trachea. Cells in complete medium were mixed with 2% low-melting-point agarose at 37°C to generate a suspension. One milliliter of cell suspension (2×10 6 cells/ml) in 2% low-melting-point agarose was injected intratracheally into the decellularized lung. Lungs were then incubated for 5 min on ice until the agarose hardened and were sectioned into approximately 2-mm thick slices using a sterile surgical blade (Fig.3A) . The lung sections were cultured in small airway epithelial cell growth medium (Lonza) for 12 days, and then fixed with 10% formaldehyde and embedded in paraffin.
Intratracheal Transplantation of Differentiated iPSCs into Bleomycin (BLM)-injured Mouse Lungs
All mouse experiments were approved by the Institutional Animal Care and Use
Committee of Niigata University. Pathogen-free female mice in a C57BL/6N genetic background (8-week-old, 18 to 20-g body weight; Charles River Laboratories, Yokohama, Japan) were anesthetized by intraperitoneal injection of 0.5 mg/g Avertin (Sigma-Aldrich), and then were administered either 4 units/kg BLM (Sigma-Aldrich) or sterile normal saline by intratracheal instillation via oropharynx intubation using a liquid aerosol device and a small animal laryngoscope (Penn-Century, Wyndmoor, PA).
Oropharynx intubation allows subsequent noninvasive cell transplantation after BLM treatment [11] . The next day, the BLM-injured mice were transplanted with fibroblasts, 
Bronchoalveolar lavage (BAL) and ELISA
After euthanasia on day 12, the trachea was cannulated with a 24-gauge catheter. The airway was lavaged with four consecutive washes of 0.5 ml sterile PBS. BAL fluid was centrifuged at 1,200 rpm for 15 min at 4°C, and the supernatants were stored at -80°C until use. Cell pellets were resuspended in 1 ml ice-cold RPMI-1640 media and centrifuged onto glass slides at 600 rpm for 10 min in a Shandon Cytospin 4 cytocentrifuge (Thermo Scientific, Waltham, USA). Cells were stained using the Diff-Quik stain set (Sysmek, Kobe, Japan). TNF-α and IL-6 concentrations in BAL fluid
were measured using solid phase sandwich ELISA kits (Invitrogen; #KMC3011 for TNF-α, #KMC0061 for IL-6) according to the manufacturer's protocol.
Wet/Dry Weight Ratio
The wet/dry weight ratio of the lung was measured to quantitatively evaluate the degree of pulmonary inflammation induced by BLM treatment according to a method described previously [22, 23] . The wet weight of lungs was measured immediately after sacrifice.
The lungs were then placed with a desiccant in an oven at 60°C for 4 days and reweighed to determine the dry weight.
Measurement of Lung Collagen
Sirius red/fast green staining was performed to evaluate collagen deposition in lung tissues. Briefly, paraffin sections of lung tissue were deparaffinized, hydrated, and incubated in 0.1% Fast Green (Wako, Tokyo, Japan; #069-00032) for 1 h at room temperature, washed in 0.5% acetic acid (Wako) for 5 min and rinsed in tap water.
Sections were then incubated in 0.1% Sirius red (Sigma-Aldrich; #365548) in saturated aqueous picric acid (Wako) for 1 h at room temperature and washed with 0.5% acetic acid for 5 min twice. After rinsing with tap water, sections were rapidly dehydrated and mounted in xylene. Collagen deposition was also assessed using a Hydroxyproline
Assay Kit (BioVision, Milpitas, CA, USA; #K555-100) according to the manufacturer's protocol. Briefly, 50 mg of homogenized lung sample were incubated in 1 ml of 6 N HCL at 110°C overnight. The hydrolyzed samples were neutralized with 1 ml of 6 N NaOH, filtered through a 0.1-mm filter, and then incubated with 100-µl Chloramine T reagent for 5 min at room temperature. One hundred microliters of the DMAB reagent were then added and incubated for 90 min at 60°C. The absorbance was measured at 570 nm, and the hydroxyproline content was calculated against a standard curve.
Statistical Analysis
The data are presented as means ± standard deviation. One-way analysis of variance (ANOVA) and Tukey-Kramer tests were used to assess the significance of differences. A P value less than 0.05 was deemed to indicate statistical significance.
RESULTS
Decision of Differentiation Medium through mRNA Expression Levels of Endoderm and Lung Epithelium Markers
We maintained mouse iPSCs and monitored the undifferentiated status of iPSCs until passage 35. iPSC pluripotency was maintained according to alkaline phosphatase (AP) staining and immunostaining for the mouse pluripotency markers SSEA1, Nanog, and OCT4. iPSCs were positive for all of these pluripotency markers (Fig. S1 ). Mouse iPSCs from passages 10 to 30 were used in the present study.
Because the GFP gene was knocked-in the mouse iPS cell line under the Nanog promoter, the undifferentiated iPSCs could be surveyed by detecting GFP expression throughout the differentiation procedure [24] . Around 4% GFP + cells remained at the end of differentiation stage 1 (day 7), whereas no GFP + cells were observed at the end of differentiation stage 2 (day 12) (data not shown). The definitive endoderm markers Sox17 and Foxa2 were expressed on day 7 ( Figure 1C ). Nevertheless, these differentiated iPS cells expressed lung epithelial markers. As shown in Figure 1A , we used Basic DM + Activin A (20 ng/ml) + Wnt3a (10 ng/ml) in stage 1 and SABM+FGF2 (50 ng/ml) in stage 2 as differentiation media in the following experiments.
Evaluation of Differentiated iPSC Phenotypes
SPC protein expression in the cytoplasm of differentiated iPSCs was confirmed by immunofluorescence ( Fig. 2A) . Additionally, 9.3±3.3% SPC-positive differentiated iPSCs were detected by flow cytometry (Fig. 2B) . TEM ultrastructural analysis showed characteristic lamellar bodies and microvilli, organelles specific to alveolar type 2 cells, in differentiated iPSCs on day 12 (Fig. 2C ). These data demonstrated that a portion of iPSCs differentiated into AECs, particularly alveolar type 2 cells.
Recellularization of Decellularized Mouse Lung Scaffold with iPSC-Derived AECs
We assessed the regenerative potential of iPSC-derived AECs in a mouse decellularized lung scaffold model that was recently demonstrated to be useful for studying functional recellularization in stem and progenitor cell populations [15, 25] . After 12 days of incubation, iPSC-derived AECs were observed to integrate into the parenchymal regions and form alveolar structures (Fig. 3B) . Some of them adopted the morphology of alveolar epithelia; i.e., they developed a rounded or flattened shape (Figs. 3B and 4) .
However, the undifferentiated iPSCs tended to proliferate in the alveolar space and form masses of cells, which resembled colonies (Figs. 3B and 4) . The fibroblasts survived but were integrated into the stroma of the lung. Immunofluorescence staining showed strong expression of SPC and T1 in tissues of the iPSC-derived AEC group, whereas few SPC-or T1 -positive cells were detected in the undifferentiated iPSC group (Fig.4) .
No SPC or T1 expression was detected in the fibroblast group (Fig. 4) . When SPC-positive cells were quantified in the recellularized mouse lung scaffolds by iPSC-derived AEC, we observed an increased percentage of SPC-positive cells (13.46±5.59%) after 12 days compared to those in in vitro differentiation D12 (9.3±3.3%). No further improvement in alveolar morphology structure or lung epithelium marker expression was observed when the culture duration was prolonged to 30 days (data not shown).
Transplantation of Differentiated iPSCs in a Lung Injury Mouse Model
To examine whether transplanted cells could home to and ameliorate lung injury, We also evaluated the long-term survival of differentiated iPSCs in BLM-injured mouse lungs. We confirmed the presence of SPC+/PKH26+ and T1α+/PKH26+ cells on day 30
after transplantation, although PKH26 fluorescence became very weak (Fig. S4B) .
Transplantation of Differentiated iPSCs Reduces Lung Inflammation and Attenuates Lung Fibrosis in BLM-treated Mice
Twelve days after intratracheal exposure of BLM, the lung tissues were severely damaged as shown by hematoxylin and eosin (HE) staining (Fig. 6A) . The lungs presented typical injuries such as disorganized epithelium, extensive inflammatory cell infiltration, interstitial thickening, collapse of the alveolar wall, and obvious cystic air spaces. Increased collagen deposition was observed by Sirius red/Fast green staining and hydroxyproline assay ( Fig. 6A and 6C ). Wet/dry weight ratios indicated that BLM treatment resulted in a significant increase in edema compared with the saline group (6.1±0.4 vs. 4.5±0.2, respectively; **P<0.01) (Fig. 6B) . Transplantation of differentiated iPSCs significantly reduced the extent of fibrosis and recovered the lung tissue structure to similar to that of the saline control (Figs. 5, S3, and 6A). A decrease in lung edema was confirmed in the iPSC-derived AEC group compared with the BLM and BLM/fibroblast groups ( Fig. 6B; #P<0 .01). Transplantation of differentiated iPSCs reduced inflammatory cell infiltration (Fig. 7A ) and decreased TNF-α and IL-6 levels in BLM-treated mice to the same levels as in the saline control ( Fig. 7B and 7C; † P>0.05).
There was no significant decrease in TNF-α and IL-6 production in the undifferentiated iPSC group compared with the BLM and BLM/fibroblasts groups ( Fig. 7B and 7C ; ▴ P>0.05). Hydroxyproline assay showed that the collagen content was decreased in the lungs of the differentiated iPSC transplantation group compared with the BLM and BLM/fibroblast groups ( Fig. 6C; #P<0 .
01). However, treatment with iPSCs-derived
AECs did not result in a return to the basal collagen level ( Fig. 6C ; *P<0.05). By contrast, there was no significant decrease in lung edema and collagen deposition in the undifferentiated iPSC group compared with the BLM group ( Fig. 6B and 6C ; ▴P>0.05).
Transplantation of fibroblasts did not rescue the lung injuries.
DISCUSSION
In the present study, we report an in vitro protocol for direct differentiation of mouse iPSCs into ~9% lung progenitor or epithelial cells in two steps. These differentiated cells express a lung progenitor marker, TTF-1, and a type II alveolar type marker, SP-C.
These cells can recellularize a decellularized mouse lung scaffold in three-dimensional culture. Finally, these differentiated cells ameliorated the BLM-induced lung injury and engrafted into the lung.
Stem cell therapy provides a new strategy for repairing severe acute and chronic lung injuries. Although some studies have demonstrated the therapeutic potential of bone-marrow-derived stem cells in rodent lung injury models [23, [26] [27] [28] , there is no evidence of a role for these stem cells in populating the lung alveolar epithelium in vivo [29] [30] [31] [32] . Recent studies have reported efficient and direct derivation of lung alveolar epithelium from murine embryonic stem cells (ESCs) [10, 11, 14, 16] for in vitro and in vivo applications. However, immune reactions and ethical issues represent barriers to their clinical application.
We modified a protocol for mouse iPSC differentiation into AECs in vitro in a 12-day period, and achieved a 9.3±3.3% yield of SPC + AEC II-like cells. However, a recent study developed a more efficient differentiation protocol for lung epithelial cells (20) .
mRNA expression of type II epithelial markers, such as SPA and SPC, was suppressed in the presence of BSA (Fig. 1B) , as reported previously [9, 33] . SABM enhanced the mRNA expression of SPA, SPC, and SPD but suppressed that of TTF1 compared with Basic DM when used during stage 2 differentiation. A primordial progenitor stage defined by TTF-1 expression is considered essential for formation of lung epithelia differentiated from endodermal cells [15, 34, 35] . Therefore, use of SABM results in enhanced differentiation of iPSCs to lung epithelia compared with Basic DM. To our knowledge, this is the first report of the three-dimensional alveolar lung structure regenerative potential and lung injury therapeutic potential of differentiated mouse iPSCs. However, because of the low efficiency of differentiation and the heterogeneity of differentiated iPSCs, the cells generated using this method are unsuitable for clinical application. A recent study reported that primordial lung progenitors can be efficiently differentiated from definitive endoderm cells through inhibition of TGFβ and BMP signaling, followed by stimulation of BMP and FGF signaling [15] . Sorting strategies can be used to enrich differentiated iPSCs. Longmire et al. used ESCs harboring a new Nkx2-1GFP knock-in reporter to derive primordial lung and thyroid progenitors and purified these progenitors using GFP for expansion in culture [15] . Soh et al. reported that lung progenitors could be enriched using the stem cell marker CD166 when differentiated from human ESCs or iPSCs [20] .
CONCLUSION
We demonstrated that mouse iPSCs could acquire the alveolar epithelial cell phenotype in vitro under specific differentiation conditions. The differentiated iPSCs possessed the potential for regenerating three-dimensional alveolar lung structures and abrogating BLM-induced acute lung injury in the mouse. 
